Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42771   clinical trials with a EudraCT protocol, of which   7044   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005696-24
    Sponsor's Protocol Code Number:MS200095-0022
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-06-14
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-005696-24
    A.3Full title of the trial
    A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen.
    Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exón 14 de MET (METex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Tepotinib Phase II study in lung adenocarcinoma harbouring MET exon 14 (METex14) skipping alterations
    Ensayo de fase II de Tepotinib en el adenocarcinoma pulmonar con alteraciones por omisión del exón 14 de MET (METex14)
    A.4.1Sponsor's protocol code numberMS200095-0022
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMerck KGaA
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck KGaA
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMerck KGaA
    B.5.2Functional name of contact pointCommunication Center
    B.5.3 Address:
    B.5.3.1Street AddressFrankfurter Str. 250
    B.5.3.2Town/ cityDarmstadt
    B.5.3.3Post code64293
    B.5.3.4CountryGermany
    B.5.4Telephone number34900810844
    B.5.6E-mailservice@merckgroup.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametepotinib
    D.3.2Product code MSC2156119J
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtepotinib
    D.3.9.2Current sponsor codeMSC2156119J
    D.3.9.3Other descriptive nameMSC2156119J
    D.3.9.4EV Substance CodeSUB177092
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nametepotinib
    D.3.2Product code MSC2156119J
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtepotinib
    D.3.9.2Current sponsor codeMSC2156119J
    D.3.9.3Other descriptive nameMSC2156119J
    D.3.9.4EV Substance CodeSUB177092
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations
    Adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exón 14 de MET (METex14)
    E.1.1.1Medical condition in easily understood language
    Lung cancer
    Cancer de Pulmón
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of tepotinib in subjects with advanced adenocarcinoma of the lung harboring
    the MET exon 14 (METex14) skipping alterations, as per objective response (confirmed complete
    response [CR] or partial response [PR]) determined according to Response Evaluation Criteria in
    Solid Tumors (RECIST) version 1.1, based on independent review.
    Evaluar la eficacia de tepotinib en sujetos con adenocarcinoma pulmonar avanzado con alteraciones por omisión del exón 14 de MET (METex14), según la respuesta (respuesta completa confirmada [RC] o respuesta parcial [RP]) determinada de acuerdo con los criterios de valoración de respuesta de tumores sólidos (Response Evaluation Criteria in Solid Tumors, RECIST) versión 1.1, basados en la revisión independiente.
    E.2.2Secondary objectives of the trial
    To further assess the efficacy of tepotinib
    - To assess tolerability and safety of tepotinib
    - To assess PK of tepotinib and its metabolite(s)
    - To assess Health-Related Quality of Life (HRQoL)
    Exploratory Objectives -To explore a possible link between biomarkers of c-Met pathway activation, other relevant oncogenic pathways in plasma, serum and tumor tissue, and the activity of tepotinib
    - To explore the QT/QTc interval concentration relationship based on Cycle 1, Day 1 and Cycle 2, Day 1 data.
    ? Evaluar más a fondo la eficacia de tepotinib.
    ? Evaluar la seguridad y la tolerabilidad de tepotinib.
    ? Evaluar la farmacocinética (FC) de tepotinib y sus metabolitos.
    ? Evaluar la calidad de vida relacionada con la salud.
    Objetivos exploratorios:
    ? Investigar una posible relación entre los biomarcadores de la activación de la vía del c-Met, otras vías oncogénicas relevantes en plasma, suero y tejido tumoral, y la actividad de tepotinib.
    ? Investigar la relación de concentración del intervalo QT/QTc basada en los datos del día 1 del ciclo 1 y del día 1 del ciclo 2.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Pharmacogenetics study: the DNA extracted for genetic variant analysis may be explored for potential genes involved in the PK, pharmacodynamics, efficacy and safety of tepotinib. Biomarkers of c-Met and other pathway activations, such as but not limited to phospho-c-Met, HGF levels, c-Met genetic mutations, and their potential correlation with prognosis and activity of tepotinib will be assessed. This consists of analyzing the type and the level of biomarkers alteration in serum or tumor tissue and evaluating their association with clinical endpoints. Blood samples for PGx will be evaluated to assess genetic variations of genes. Pharmacogenetics testing might include assessment of genetic polymorphisms responsible for drug metabolism and transport genes and may also be used for assessing polymorphisms linked to Caucasian or Asian descent. Other biomarkers and technologies may be included, the scientific relevance of which emerges at the time of the planned analysis for subjects included in the trial.
    Estudio de farmacogenética: el ADN extraído para el análisis de la variante genética puede investigarse para detectar posibles genes implicados en la FC, farmacodinámica, la eficacia y la seguridad de tepotinib. Se evaluarán los biomarcadores de c-Met y otras activaciones de vías, como fosfo-c-Met,niveles de HGF, mutaciones genéticas de c-Met, entre otras, y su posible correlación con el pronóstico y la actividad de tepotinib. Esto consiste en analizar el tipo y el nivel de alteración de biomarcadores en suero o tejido tumoral y evaluar su asociación con los criterios de valoración clínicos.
    Las muestras de sangre de FG se analizarán para evaluar las variaciones genéticas de los genes. Las pruebas de farmacogenética pueden incluir la evaluación de polimorfismos genéticos responsables del metabolismo del fármaco y los genes transportadores y también pueden utilizarse para evaluar polimorfismos relacionados con ascendencia caucásica o asiática. Pueden incluirse otros biomarcadores y tecnologías, cuya relevancia científica surge en el momento del análisis programado de los sujetos incluidos en el ensayo.
    E.3Principal inclusion criteria
    "1. Histologically confirmed advanced adenocarcinoma of the lung, having failed at least one line of systemic therapy, including a platinum-doublet-containing regimen, but having failed a maximum of 2 lines of active therapy;
    2. METex14 skipping alterations, as determined by the central laboratory. Both, archival and
    fresh biopsies are acceptable; In case METex14 skipping alteration has been observed in a subject in a pre-trial setting, it should be ensured that sufficient tissue is available for re-testing before trial entry. Only subjects with METex14 skipping mutation based on trial central testing will be
    enrolled into the trial.
    3. Signed, written informed consent by subject or legal representative prior to any trial-specific screening procedure;
    4. Male or female, ? 18 years of age (or having reached the age of majority according to local laws and regulations, if the age of majority is > 18 years of age);
    5. Measurable disease in accordance with RECIST version 1.1;
    6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1."
    ?1. Adenocarcinoma pulmonar avanzado histológicamente confirmado, tras fallar, como mínimo, una línea de tratamiento sistémico con doblete de platino, pero no se han tolerado un máximo de 2 líneas de tratamiento activo;
    2. Alteraciones por omisión del METex14, determinado por el laboratorio central. Se aceptan tanto las biopsias de archivo como las frescas. En el caso de observarse la alteración por omisión del METex14 en un sujeto en un ámbito de pre-ensayo, deberá garantizarse que se dispone de tejido suficiente para repetir la prueba antes de entrar en el ensayo. Solo los sujetos con una mutación por omisión del METex14 basada en las pruebas centrales del ensayo podrán inscribirse en el ensayo.
    3. Consentimiento informado por escrito y firmado por el sujeto o el representante legal antes de cualquier procedimiento de selección específico del ensayo;
    4. Hombre o mujer, ?18 años (o que haya alcanzado la mayoría de edad en conformidad con las leyes y regulaciones locales, si la mayoría de edad es >18 años);
    5. Enfermedad medible de acuerdo con la versión RECIST 1.1;
    6. Estado general del Grupo Oncológico Cooperativo del Este (EG ECOG) de 0 o 1.?
    E.4Principal exclusion criteria
    1. Subjects with characterized EGFR (documented results; local testing acceptable) that predict sensitivity to EGFR-therapy, including, but not limited to exon 19 deletions and exon 21 alterations;
    2. Subjects with characterized ALK rearrangements (documented results; local testing acceptable);
    3. Active brain metastases (defined as neurologically stable for < 4 weeks and/or symptomatic and/or requiring treatment with steroids and/or leptomeningeal disease). Subjects must have completed any prior treatment for brain metastases ? 4 weeks prior to start of therapy (? 2 weeks for stereotactic radiosurgery/gamma knife). Subjects who are neurologically stable on symptomatic therapy with anticonvulsants with low drug interaction risk or whose steroids
    are being tapered are eligible. Asymptomatic untreated brain metastases ? 1cm are eligible;
    4. Any unresolved toxicity Grade 2 or more according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) from previous anticancer therapy;
    5. Need for transfusion within 14 days prior to the first dose of trial treatment;
    6. Prior chemotherapy, biological therapy, radiation therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of trial treatment;
    7. Inadequate hematological, liver, renal, cardiac function; 8. Prior treatment with other agents targeting the HGF/c-Met pathway; 9. Past or current history of neoplasm other than NSCLC, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years (for a full list of exlustion criteria please see the study protocol).
    1. Sujetos con EGFR caracterizado (resultados documentados, pruebas locales aceptables) que pronostican la sensibilidad al tratamiento EGFR, incluido las eliminaciones del exón 19 y las alteraciones del exón 21, entre otros.
    2. Sujetos con reordenaciones caracterizadas en el ALK (resultados documentados; pruebas locales aceptables);
    3. Metástasis cerebrales activas (definidas como estables neurológicamente durante <4 semanas y/o sintomáticas y/o que requieren tratamiento con corticosteroides y/o enfermedad leptomeníngea). Los sujetos deben haber terminado cualquier tratamiento anterior para la metástasis cerebral ?4 semanas antes del inicio del tratamiento (?2 semanas en el caso de la radiocirugía estereotáctica/gamma knife). Son sujetos aptos aquellos que sean neurológicamente estables en el tratamiento sintomático con anticonvulsivos con poco riesgo de interacción de fármacos o cuyos corticosteroides estén reduciéndose. Serán aptos los pacientes con metástasis cerebrales asintomáticas no tratadas ?1 cm;
    4. Cualquier toxicidad no resuelta de grado 2 o superior según Los criterios comunes de terminología para acontecimientos adversos del Instituto Nacional del Cáncer (National Cancer Institute Common Terminology Criteria for Adverse Events, NCI CTCAA) del anterior tratamiento antineoplásico;
    5. Necesidad de transfusión en un plazo de 14 días antes de la primera dosis del tratamiento del ensayo;
    6. Quimioterapia, tratamiento biológico, radioterapia u otro tratamiento antineoplásico en investigación (no incluida la radioterapia paliativa en los centros focales) en un plazo de 21 días antes de la primera dosis del tratamiento del ensayo;
    7. Función cardiaca, renal, hepática y hematológica inadecuada;
    8. Tratamiento previo con otros fármacos dirigidos a la vía del HGF/c-Met;
    9. Antecedentes de neoplasma distinto de CPNM o neoplasma actual, exceptuando el cáncer de piel no melanomatoso tratado y curado, carcinoma localizado del cuello uterino u otros cánceres tratados y curados y sin indicios de enfermedad durante al menos 5 años (para obtener una lista completa de los criterios de exclusión, véase el protocolo del estudio).
    E.5 End points
    E.5.1Primary end point(s)
    Objective response rate
    Tasa de respuesta objetiva
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline up to 20 months
    Inicio hasta 20 meses
    E.5.2Secondary end point(s)
    1. Objective response rate assessed as per Investigator
    2. Duration of response as assessed by independent review committee
    3. Duration of response as assessed by investigator
    4. Objective disease control Rate as assessed by independent review committee
    5. Objective disease control Rate as assessed by investigator
    6. Progression free survival as assessed by independent review committee
    7. Progression free survival as assessed by investigator
    8. Overall survival
    9. Number of subjects with TEAEs and deaths
    10. Number of subjects with markedly abnormal vital signs, ECG, physical examination and ECOG PS.
    11. Health Related Quality of Life Parameters
    12. Maximum plasma concentration (Cmax) of Drug
    13. Volume of distribution (Vz/F) of drug
    14. Total Clearance (Cl) of drug
    1. Tasa de respuesta objetiva evaluada por el investigador
    2. Duración de la respuesta evaluada por el comité de revisión independiente
    3. Duración de la respuesta evaluada por el investigador
    4. Tasa de control de la enfermedad objetiva evaluada por el comité de revisión independiente
    5. Tasa de control de la enfermedad objetiva evaluada por el investigador
    6. Supervivencia sin progresión evaluada por el comité de revisión independiente
    7. Supervivencia sin progresión evaluada por el investigador
    8. Supervivencia general
    9. Número de sujetos con AAST y muertes
    10. Número de sujetos con constantes vitales claramente alteradas, ECG, exploración física y EG ECOG.
    11. Parámetros de calidad de vida relacionada con la salud
    12. Concentración plasmática máxima (Cmáx) del fármaco
    13. Volumen de distribución (Vz/F) del fármaco
    14. Aclaramiento total (Cl) del fármaco
    E.5.2.1Timepoint(s) of evaluation of this end point
    2, 3, 6, 7: Baseline until PD/ death within 84 days of last tumor assessment; assessed up to 20 months
    8: Baseline until death , assessed up to 20 months
    1, 4, 5, 10, 11: Baseline up to 20 months
    9: From the first dose of study drug administration until 33 days after the last dose of study drug administration, assessed up to 20 months
    12 to 14: pre-dose, at 1.5 hours post-dose and at 4 hours post-dose on Cycle 1, Day 1 and on Cycle 2, Day 1
    2, 3, 6, 7: Inicio hasta FD/muerte en un plazo de 84 días de la última evaluación tumoral; evaluado hasta 20 meses
    8: Inicio hasta la muerte, evaluado hasta 20 meses
    1, 4, 5, 10, 11: Inicio hasta 20 meses
    9: Desde la primera dosis de la administración del fármaco del estudio hasta 33 días después de la última dosis de la administración del fármaco del estudio; evaluado hasta 20 meses
    De 12 a 14: predosis, 1,5 horas post-dosis y 4 horas post-dosis en Ciclo 1, Día 1 y Ciclo 2, Día 1
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned16
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA30
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    France
    Germany
    Italy
    Japan
    Poland
    Spain
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Time point at which all subjects have discontinued and two thirds of the subjects have died.
    Momento en el que todos los sujetos hayan interrumpido el ensayo y dos tercios de los sujetos hayan muerto.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 35
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 25
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    the elderly
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 65
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    normal treatment
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-06-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-05-27
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA